Iron Triangle Partners LP acquired a new position in 10x Genomics (NASDAQ:TXG - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 1,000,000 shares of the company's stock, valued at approximately $8,730,000. 10x Genomics makes up 1.4% of Iron Triangle Partners LP's holdings, making the stock its 27th largest holding. Iron Triangle Partners LP owned approximately 0.82% of 10x Genomics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of TXG. Raymond James Financial Inc. bought a new stake in shares of 10x Genomics in the 4th quarter worth $431,000. First Trust Advisors LP raised its stake in shares of 10x Genomics by 159.9% in the 4th quarter. First Trust Advisors LP now owns 217,558 shares of the company's stock worth $3,124,000 after buying an additional 133,841 shares in the last quarter. Stifel Financial Corp raised its stake in shares of 10x Genomics by 28.3% in the 4th quarter. Stifel Financial Corp now owns 20,997 shares of the company's stock worth $302,000 after buying an additional 4,628 shares in the last quarter. Hsbc Holdings PLC raised its position in shares of 10x Genomics by 25.3% during the fourth quarter. Hsbc Holdings PLC now owns 121,804 shares of the company's stock worth $1,755,000 after purchasing an additional 24,562 shares during the period. Finally, Voya Investment Management LLC raised its position in shares of 10x Genomics by 6.9% during the fourth quarter. Voya Investment Management LLC now owns 76,789 shares of the company's stock worth $1,103,000 after purchasing an additional 4,943 shares during the period. Institutional investors own 84.68% of the company's stock.
10x Genomics Price Performance
Shares of TXG traded up $0.01 during mid-day trading on Wednesday, reaching $13.38. The company had a trading volume of 808,730 shares, compared to its average volume of 3,358,340. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.38. The company's 50-day moving average is $13.03 and its 200-day moving average is $10.71. The company has a market capitalization of $1.67 billion, a P/E ratio of -19.09 and a beta of 2.00.
10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm had revenue of $172.91 million during the quarter, compared to analysts' expectations of $139.36 million. During the same period last year, the firm posted ($0.32) EPS. The business's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, equities analysts expect that 10x Genomics will post -1.43 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts have recently issued reports on the company. JPMorgan Chase & Co. cut their target price on 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. The Goldman Sachs Group lowered their price target on 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a report on Monday, May 12th. Stephens reaffirmed an "overweight" rating and issued a $14.00 target price on shares of 10x Genomics in a research report on Thursday, May 15th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday. Finally, Bank of America increased their price objective on 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $13.54.
Check Out Our Latest Stock Analysis on TXG
Insider Activity at 10x Genomics
In related news, CEO Serge Saxonov sold 9,348 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer directly owned 945,892 shares of the company's stock, valued at $13,043,850.68. This trade represents a 0.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the sale, the insider owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock valued at $539,865 in the last three months. Corporate insiders own 10.03% of the company's stock.
About 10x Genomics
(
Free Report)
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Featured Articles
Before you consider 10x Genomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 10x Genomics wasn't on the list.
While 10x Genomics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
